Mivuxin (Noradrenaline Tartrate)

Noradrenaline tartrate, the active ingredient in Mivuxin, is a sympathomimetic amine presented as an intravenous solution for intravenous use. It is employed to raise blood pressure in acute hypotensive states such as septic shock and cardiac arrest. GNH USA supplies Mivuxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mivuxin acts on the sympathetic nervous system to restore vascular tone in critical care settings. - Hypotension: increases systemic vascular resistance to achieve target arterial pressure. - Septic shock: counteracts vasodilatory shock by constricting peripheral vessels and improving perfusion. - Cardiac arrest: provides immediate pressor support during resuscitation to maintain coronary and cerebral blood flow.

Mivuxin may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Tachycardia: rapid heart rate due to β1 stimulation. - Headache: result of abrupt vascular changes. - Anxiety or restlessness: central sympathetic activation. - Peripheral ischemia: reduced blood flow to extremities.

Serious or Rare Side Effects: - Severe hypertension: excessive vasoconstriction leading to organ damage. - Myocardial ischemia or infarction: increased cardiac workload. - Arrhythmias: potentially life‑threatening rhythm disturbances. - Tissue necrosis at infusion site: extravasation injury.

When using Mivuxin, clinicians should observe several safety measures to minimise risk. - Dose titration: adjust infusion rate based on continuous blood pressure monitoring. - Cardiovascular monitoring: maintain invasive arterial line and ECG throughout therapy. - Contraindications: avoid in patients with pheochromocytoma or uncontrolled hypertension. - Drug interactions: review concomitant use of MAO inhibitors or ergot alkaloids. - Pregnancy: consider only if potential benefit outweighs fetal risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenaline tartrate can interact with several agents that modify vascular tone or catecholamine metabolism.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis due to additive catecholamine effects. - Ergot alkaloids: potent vasoconstriction may lead to severe ischemia. - Tricyclic antidepressants: increased sympathetic activity.

Moderate Interactions (Monitor Closely): - Vasodilators (e.g., nitroglycerin): may blunt pressor response, requiring dose adjustments. - ACE inhibitors or ARBs: can enhance hypotensive episodes if not carefully titrated. - Calcium channel blockers: may affect cardiac output and require close hemodynamic monitoring.